Reimagining the future of biopharma manufacturing

McKinsey Public & Social Sector Insights

Insights on Life Sciences BiotechnologyLeveraging digital and analytics advances can unlock significant value for biopharma companies through gains in quality, speed, agility, and resilience.

CROs and biotech companies: Fine-tuning the partnership

McKinsey

Emerging biotechnology companies are less satisfied than large pharmaceutical companies with their contract research organizations (CROs). Insights on Life Sciences Biotechnology

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What are the biotech investment themes that will shape the industry?

McKinsey

Insights on Life Sciences BiotechnologyFrom 2019 to 2021, venture capitalists plowed $35 billion into biotech companies with advanced platform technologies that could transform the industry.

How the European biotech sector can navigate turbulent times

McKinsey Public & Social Sector Insights

Insights on Life Sciences BiotechnologyThe recent market downturn has affected biotechs worldwide. But the fundamentals are still strong in Europe, where companies have an opportunity to lead the next phase of bioscience innovation.

Building pharma pipelines using a socioeconomic lens

McKinsey

Insights on Life Sciences Biotechnology InnovationHarnessing advances in science and technology can deliver transformative therapies faster while reducing the socioeconomic burden of disease.

A biotech survival kit for a challenging public-market environment

McKinsey Public & Social Sector Insights

Insights on Life Sciences Biotechnology Public SectorAfter a decade of plenty, biotechs are grappling with a challenging market. To emerge strongly, they can streamline R&D and G&A expenses, evaluate new financing options, and consider mergers with other biotechs.

Building a global biotech: Taking a first-time launch into international markets

McKinsey

Insights on Life Sciences Biotechnology Globalization StrategyEstablishing an international presence with a first launch is a challenge, but learning from others’ experiences can help biotechs avoid missteps and maximize their chances of success.

How biotechs can rethink their strategies after the market downturn

McKinsey

Insights on Life Sciences Health Care BiotechnologyBiotech stocks have taken a hit, but the sector will probably rebound. Companies can navigate the downturn by scrutinizing cash management and financing and rethinking paths to long-term value creation.

Self-learning: The dawn of a new biomedical R&D paradigm

McKinsey

Insights on Life Sciences BiotechnologyScience and technology are driving breakthroughs at each stage of the biomedical R&D value chain. Enhancing feedback loops among them could unleash a self-learning model that would benefit patients.

Three imperatives for R&D in biosimilars

McKinsey Public & Social Sector Insights

Insights on Life Sciences BiotechnologyThe biosimilars market is poised to grow over the next decade. Here’s how companies can accelerate time to market, reduce R&D costs, and improve productivity.

India as a pharma innovation hub: An interview with Dr. Reddy’s G. V. Prasad

McKinsey Public & Social Sector Insights

Future of Asia Biotechnology Pharmaceuticals Asia-PacificThe cochairman and managing director of the pharma multinational believes India’s competence in new biology, clinical development, and chemistry will increase its global competitiveness.

Can European biotechs achieve greater scale in a fragmented landscape?

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeWorld-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech.

Gene-therapy innovation: Unlocking the promise of viral vectors

McKinsey

Insights on Pharmaceuticals & Medical Products Pharmaceuticals BiotechnologyViral-vector gene therapies show great promise, but the full extent of their clinical impact in the long term is not yet certain. Success depends on innovative solutions that remain under development.

Forward Thinking on the Bio Revolution with Jason Kelly and Dr. Michelle McMurry-Heath

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyThe leaders of Gingko Bioworks and the BIO organization discuss the future of biological technologies, from developing vaccines faster to changing how we produce food.

What’s ahead for biotech: Another wave or low tide?

McKinsey

Insights on Pharmaceuticals & Medical Products Venture capital BiotechnologyEven in tough times, investor expectations and deal making in biotech are surging. Can the sector maintain its strong growth?

An inflection point for biosimilars

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology PharmaceuticalsWith rising US adoption, biosimilars are gathering even more momentum. Successful companies will innovate their commercial models, rethink their portfolio management, and accelerate their R&D.

Precision medicine in practice: Strategies for rare cancers

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology Pharmaceuticals Oncology/CancerThe small number of people with rare diseases raises challenges for the development and launch of all therapies for such conditions, but rare cancers face extra barriers to widespread treatment.

The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies

Frost & Sullivan Manufacturing

Shamsudeen added: “With biotechnological processes producing novel molecules, metal-based antimicrobials can profile efficient solutions to infection care and health. San Antonio– Sept.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

Healthcare News Press Releases biopharma biopharmaceutical biotechnology biotherapeutics COVID-19 vaccine logistics DNA drug mrna pharma Pharmaceutical research RNA therapeutics vaccine

Infographic: Biotech hot spots in a fragmented European landscape

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyWe mapped out 1,382 biotechs based in Europe and some interesting themes emerged.

Infographic: Building the European biotech sector with world-class science and innovation

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope is a powerhouse in scientific publishing with roughly twice the output of the United States and three times that of China.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Pharmaceuticals & Medical Products BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market

Frost & Sullivan

Pharmaceuticals and biotechnology, IVD, advanced medical technologies, medical imaging and informatics, and digital health expected to hit over $2.6

Infographic: Capital landscape for European biotechs is maturing, but it continues to trail the United States

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope’s biotech sector has made meaningful progress in attracting capital. However, raising more capital will be essential to the continued growth of this sector.

Infographic: Biotech in Europe: Driving the next act

McKinsey

Insights on Life Sciences BiotechnologyHow can biotechs and investors succeed in the future? To scale up innovation, industry stakeholders need to focus on several key areas.

Infographic: The McKinsey Biotech Innovation Index

McKinsey

Insights on Pharmaceuticals & Medical Products Biotechnology EuropeEurope may be catching up with the United States in biotech innovation and funding. Its overall score on the Biotech Innovation Index improved by 20 percent in 2015–17 and 2018–20.

LaVoieHealthScience Announces Appointment of Nick Hennen as Head of Media, Boston, Building Out Media Training for Staff and Clients

LaVoie Health Science Blog

I’m looking forward to bringing impactful media solutions to our biotechnology, medical technology, pharmaceutical, and consumer wellness clients through doing what I most love to do – earning influential media placements.”.

Are You Ready for New Leadership??

Peter Simoons

” Head of Alliance Management – Biotechnology Research Organisation. Recently we’ve noticed rising interest in alliances & partnerships. My alliance partner Anoop Nathwani and I hear it in the many conversations that we have.

There is a Name for What I Do!

Peter Simoons

It is one of the best-run online learning experiences I have attended” Head of Alliance Management – Biotechnology Research Organisation. It must have been twenty years ago that I signed up for my first course on strategic alliances.

2021 Preview: A 360-Degree Global Market View

LaVoie Health Science Blog

The “ 2021 Preview: A 360 Degree Global Market View, ” virtual webinar was designed to discuss global market trends on public and private United States, Europe, and China markets, JPM virtual week in January 2021, and more.

LaVoieHealthScience Bolsters Commercial Strategic Communications Expertise with the Hiring of Deborah Plumstead as Vice President

LaVoie Health Science Blog

Plumstead brings over 20 years of experience leading product and corporate public relations initiatives for companies in the pharmaceutical, biotechnology, and medical device sectors.

LaVoieHealthScience Builds on 2020 Momentum with an Updated Team Roster to Meet Client Growth in 2021

LaVoie Health Science Blog

In addition to expanding its strategic communications team, LHS also debuted its virtual webinar series with Biotechnology Innovation Organization, including a 2021 Preview: A 360-Degree Global Market View. BOSTON & NEW YORK – January 7, 2021.

Account Executive

LaVoie Health Science Blog

Successful candidate will be a detail-oriented self-starter with 3-5 years of agency or related experience in healthcare in particular for biotechnology and pharmaceutical industries or technology. Join a health science focused integrated communications agency and be part of the agency’s second phase of growth. Strong detail oriented public relations/communications professional needed for growing life science/biopharmaceutical practice.

The Hot-melt Adhesives Product Landscape: Are Sustainability Trends Reforming It?

Frost & Sullivan Manufacturing

The end-use industries that consume HMAs are undergoing several transformations that will influence their use. They are increasingly seeking de-bondable HMA solutions to avoid material waste, save manufacturing costs, and contribute to a reduced environmental footprint.

LaVoieHealthScience Announces Appointment of Joseph T. Schepers as Senior Vice President of Investor Relations and Financial Communications

LaVoie Health Science Blog

Further Strengthens IR Leadership Team and Supports Integrated Strategic Communications Capabilities and Continued Business Growth. link].

Back to BIO In Person: An Interview with Donna LaVoie, President & CEO

LaVoie Health Science Blog

GB: Donna, you have been presenting How to Tell Your Company Story in 15 Slides at the Biotechnology Innovation Organization International Convention for many years. by Gemma Bakx, SVP, Investor Relations and ESG.

How DSM Merged with Firmenich: When Capabilities Complement each other

Frost & Sullivan Manufacturing

DSM has a strong portfolio of bio-based ingredients that will be complemented by Firmenich’s long-standing experience in natural and biotechnology-derived ingredients. In May 2022, DSM and Firmenich announced their plans to merge together.

DSM Merger with Firmenich – A Fusion of Complementary Capabilities

Frost & Sullivan

DSM has a strong portfolio of bio-based ingredients that will be complemented by Firmenich’s long-standing experience in natural and biotechnology-derived ingredients. In May 2022, DSM and Firmenich announced their plans to merge together.

25 Board Reporting Software Options

ClearPoint Strategy

Industries It Serves: Hospital & Health Care • Banking • Biotechnology • Financial Services • Automotive • Executive Offices • Government • IT and Services • Mining & Metals • Nonprofit.